Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
ABBOTT PARK, Ill., and
"Hepatitis C is a serious global health concern, with 170 million people
currently infected by six different HCV genotypes," said
"ABT-450 demonstrated favorable potency in vitro across various HCV
genotypes and highly resistant strains," said
Phase 1 Study Design
The Phase 1, double-blind, placebo-controlled study for ABT-450 announced today is a single, ascending oral dose trial in healthy volunteers.
About the Hepatitis C Virus
Hepatitis C is a liver disease affecting more than 170 million people worldwide. The virus is spread through direct contact with the blood of an infected person. Hepatitis C increases a person's risk of developing chronic liver disease, cirrhosis, liver cancer and death.
Liver disease associated with HCV infection is growing rapidly, and current therapies only provide sustained benefit in about half of patients with the genotype 1 form of the virus. Specifically targeted antiviral therapies for HCV, such as NS3/4a protease inhibitors, may have the potential to increase the proportion of patients in whom the virus can be eradicated.
Enanta Pharmaceuticals is a research and development company that uses its
novel chemistry approach and drug discovery capabilities to create best-in-
class small molecule drugs in the anti-infective field. Enanta is developing
novel protease, polymerase and cyclophilin-based inhibitors targeted against
the Hepatitis C virus (HCV). Additionally, the company has created a new
class of macrolide antibiotics, called Bicyclolides, which overcomes bacterial
resistance. Antibacterial focus areas include superbugs, respiratory tract
infections and intravenous and oral treatments for hospital and community
MRSA. Enanta is a privately held company headquartered in
Abbott is working to advance the treatment of Hepatitis C (HCV) through a multifaceted discovery and development program that leverages the company's deep experience in antiviral medicines. Compounds in various states of development include protease inhibitors (ABT-450) and polymerase inhibitors (ABT-333 and ABT-072). In addition to developing HCV therapies, Abbott also offers laboratory tests for patient diagnosis, blood screening tests for hospitals and blood banks, and molecular diagnostic tests to measure HCV viral load and resistance.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 69,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's web site at http://www.abbott.com.
SOURCE Abbott; Enanta Pharmaceuticals